A total of 232 high-grade serous ovarian cancer patient tissue chips (including 114 PARP inhibitor-resistant patients and 118 PARP inhibitor-sensitive patients) were selected to evaluate the clinical significance of RORα, ECM1, and VEGFR2 in ovarian cancer (Figure 8A). This evidence concerns the gene RORA and ovarian serous adenocarcinoma.